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Abstract. Background: A variety of molecular markers have been evaluated for the development of a non-invasive approach to
the diagnosis of colorectal cancer. We aimed to validate the diagnostic accuracy, using the same threshold as in the previous pilot
study, of fluorescent long DNA test as a relatively simple and inexpensive tool for colorectal cancer detection.
Methods: A case-control study was conducted on 100 healthy subjects and 100 patients at first diagnosis of colorectal can-
cer. Human long-fragment DNA in stool was quantified by fluorescence primers and a standard curve and expressed in DNA
nanograms.
Results: We validated the 25-ng value, which emerged as the most accurate cut-off in the pilot study, obtaining 79% (95% CI,
71–87%) sensitivity and 89% (95% CI, 83–95%) specificity. Specificity was very high for all cut-off values (15–40 ng) analyzed,
ranging from 78 to 96%. Sensitivity was only slightly lower, reaching 84% at the lowest cut-off and maintaining a good level at
the higher values. Diagnostic potential was independent of gender, age and tumor site.
Conclusion: Fecal DNA analysis is a non-invasive and fairly simple test showing high diagnostic potential. These character-
istics, together with the small amount of stool required, make it potentially suitable to be used alongside or as an alternative
to current non-invasive screening approaches. Our next step will be to validate these results in a large-scale cohort study of a
screening population, which is needed prior to implementation into clinical practice.
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1. Introduction
Colorectal cancer (CRC) is the third most common
malignancy in the world [16]. Screening for CRC has
great potential to reduce morbidity and mortality from
the disease, but currently only a small portion of eligi-
ble individuals undergo testing for early diagnosis [11].
Moreover, there is ongoing debate about the best and
most effective method to use in CRC screening pro-
grams. With the exception of the Fecal Occult Blood
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Test (FOBT), all currently available tools are both inva-
sive and expensive [11]. Molecular stool testing could
provide a valid alternative to conventional methods
in terms of compliance and practicability. New tests
based on molecular markers and aimed at detecting
neoplastic cells or cell products in stool have there-
fore been developed and are currently being evaluated.
A variety of genetic and epigenetic alterations, which
commonly occur during evolution from normal colon
mucosa to adenoma and carcinoma, such as K-ras, p53,
APC gene mutations, microsatellite instability or epi-
genetic events, have been investigated [1,4,6,12–15,
19–22,24]. The results from these studies have shown
that individual molecular alterations are present in the
stool of only a fraction of patients and are therefore
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characterized by low sensitivity in detecting colorectal
cancer. Multiple mutation analyses have improved test
sensitivity, but with a corresponding increase in costs
and test execution time [6,14,20]. For these reasons,
none of the above methods can be used in early diag-
nosis programs [3,23].
DNA integrity analysis of genomic DNA extracted
from stool represents a moderately inexpensive and
relatively rapid test [5,26,28]. In particular, the fluores-
cence long DNA (FL-DNA) method, which was devel-
oped in our laboratory and is based on the quantifica-
tion of stool DNA using fluorescent primers, showed
interesting results in a pilot case-control study [5].
In the present confirmatory study, we aimed to val-
idate the results from the pilot study, using the same
threshold as before, in a larger and independent case
series.
2. Materials and methods
2.1. Case series
One hundred patients with primary CRC at first di-
agnosis and 100 healthy individuals were entered onto
the study. Patients were enrolled from the Departments
of Gastroenterology of Morgagni-Pierantoni Hospital
(Forlì, Italy) and Bufalini Hospital (Cesena, Italy), the
Department of Oncology of Infermi Hospital (Rim-
ini, Italy), and the Department of Surgery and Oncol-
ogy, University of Palermo (Palermo, Italy) from Jan-
uary 2005 to December 2006. Stool was collected 5–
7 days after colonoscopy in order to avoid traumatic
artifacts due to bleeding or inflammation, which could
produce falsely elevated long DNA levels, and to allow
restoration of normal bowel function. Healthy donors
were recruited over the same period from laboratory
staff members of the same hospitals and their families,
and frequency matched by sex and age (55, 56–70,
>70 years). All healthy donors had a negative FOBT.
Stools from patients and healthy donors were frozen
immediately and stored at −80◦C for a maximum of
2 months.
Diagnosis of cancer was histologically confirmed
and pathological stage was defined according to Dukes’
classification: 17 tumors were classified as stage A,
45 as stage B, 29 as stage C and 7 as stage D. Informa-
tion was not available for 2 patients. Moreover, 34 can-
cers were located in the ascending colon, 45 in the de-
scending colon, and 5 in the transverse colon, while
16 were rectal cancers.
The study protocol was reviewed and approved by
the local Ethics Committee of each center taking part.
2.2. DNA purification
Approximately 200 mg of stool were thawed at
room temperature and homogenized with 10 ml of
TE-9 buffer (0.5 mol/l Tris-HCl pH 9, 20 mmol/l
EDTA and 10 mmol/l NaCl). After centrifugation at
5000g for 15 min to remove all particulate matter, the
supernatant was transferred to a tube containing 350 µl
of ammonium acetate 7.5 mol/l (M-Medical, Florence,
Italy) and 19 ml of ethanol 100% (Carlo Erba, Milan,
Italy). DNA was recovered by centrifugation at 5000g
for 15 min at room temperature, suspended in 1.6 ml
of ASL buffer and purified by QIAamp DNA Stool Kit
(Qiagen, Hilden, Germany).
2.3. Fluorescence long DNA (FL-DNA) analysis
The fluorescence intensity of each sample-specific
PCR product was determined with fluorescent-labelled
primers, as previously described [5]. Briefly, p53 exons
5–8 and fragments 1–4 of APC exon 15 were amplified
in a final volume of 25 µl containing 2 µl of stool DNA,
0.4 µM of each primer, 200 µM of deoxynucleotide
(Takara Bio Inc, Shiga, Japan), 1× reaction buffer with
3.5 mM MgCl2 (Qiagen), and 1 U of Taq polymerase
(Qiagen). The reaction mixture was subjected to 32 cy-
cles: 60 s at 94◦C and then 60 s at 60◦C for p53 exons,
and 58◦C for APC fragments, followed by incubation
at 72◦C for 60 s. Primers used were end-labeled with
fluorochromes provided by Applied Biosystems (Fos-
ter City, CA, USA).
The p53 exons were amplified simultaneously in
a single reaction mixture. Primer sequences were:
exon 5: 5S FAM-CTC TTC CTG CAG TAC TCC CCT
GC and 5AS GCC CCA GCT GCT CAC CAT CGC
TA; exon 6: 6S GAT TGC TCT TAG GTC TGG CCC
CTG and 6AS HEX-GGC CAC TGA CAA CCA CCC
TTA ACC; exon 7: 7S FAM-GTG TTG TCT CCT
AGG TTG GCT CTG and 7AS CAA GTG GCT CCT
GAC CTG GAG TC; exon 8: 8S ACC TGA TTT CCT
TAC TGC CTC TGG C and 8AS HEX-GTC CTG CTT
GCT TAC CTC GCT TAG T. The four APC fragments
were amplified in two different mixes (mix 1, frag-
ments 3 and 4; mix 2, fragments 1 and 2). Sequences
were as follows: fragment 3: 3S GAT GTA ATC AGA
CGA CAC AG and 3AS HEX-GGC AAT CGA ACG
ACT CTC AA; fragment 4: 4S FAM-CAG TGA TCT
TCC AGA TAG CC and 4AS AAA TGG CTC ATC
GAG GCT CA; fragment 1: 1S AAC TAC CAT CCA
GCA ACA GA and 1AS HEX-TAA TTT GGC ATA
AGG CAT AG; fragment 2: 2S FAM-CAG TTG AAC
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TCT GGA AGG CA and 2AS TGA CAC AAA GAC
TGG CTT AC. DNA from each sample was quantified
on a standard curve of genomic DNA (1, 2, 5, 10 and
20 ng) normalized to 100, and expressed as nanograms.
Electrophoresis was carried out using a 3100 Avant
Genetic Analyzer (Applied Biosystems) equipped with
GeneScan Analysis 3.7. The final FL-DNA value was
obtained by analyzing the fluorescence intensity of
each sample-specific PCR product. The quantification
of each sample was calculated by reference to a stan-
dard curve (1, 2, 5, 10 and 20 ng) of genomic DNA and
expressed as nanograms. We evaluated three different
standard curves, one for p53 exons 5–8, one for APC
fragments 1–2 and one for APC fragments 3–4.
All samples were run in duplicate and only inter-
sample variations of less than 15% were accepted. In
all other cases the determination was performed on a
third sample, and was required in <10% of the entire
series. All samples were amplified with a mix contain-
ing 25 attograms of a plasmid with a control sequence
to test for the presence of Taq inhibitors.
2.4. Statistical analysis
The objective of this validation study was to confirm
sensitivity and specificity of the DNA test using the
best cut-off value identified in the pilot study [5]. The
population size was based on the results of the pilot
study, which reported 76% sensitivity and 93% speci-
ficity using the best cut-off of 25 ng. It was estimated
that, with 100 patients and 100 controls, the two-sided
95% confidence intervals, using the normal approxi-
mation, would extend 0.08 and 0.05 from the expected
sensitivity and specificity, respectively.
The analysis of the FL-DNA concentration, con-
sidered as a continuous variable, was carried out by
receiver operating characteristic (ROC) curve analy-
sis. In the ROC curve, the true positive rates (sen-
sitivity) were plotted against the false positive rates
(1-specificity) for all classification points. Sensitiv-
ity, specificity and relative 95% confidence intervals
(95% CI) were calculated using different cut-off val-
ues. The median values of amplified DNA levels in
controls and patients were compared using the non-
parametric median test.
A breakdown analysis for clinical and pathologi-
cal subgroups was performed with explorative intent.
Subgroup sensitivity was analyzed by the chi-square
test.
3. Results
Values of amplified DNA ranged from 0 to 246 ng
in healthy donors and from 0 to 731 ng in patients,
with median values of 0 and 64 ng, respectively
(p < 0.0001) (Table 1). FL-DNA median values were
independent of gender and age. In patients, fecal DNA
levels were also independent of tumor size and site and
slightly lower, albeit not significantly, in the few pa-
tients with Dukes’ stage D tumors compared to those
with earlier stage tumors (Table 1).
ROC curve analysis showed an area under the curve
(AUC) of 0.870 (95% CI: 0.82–0.92) (Fig. 1). The di-
agnostic potential of different FL-DNA cut-off values
from 15 to 40 ng was evaluated (Table 2). Specificity
was very high for all the cut-offs analyzed, varying
from 78 to 96%. Sensitivity was only slightly lower,
reaching 84% at the lowest cut-off (15 ng) and main-
taining good levels up to the highest cut-off (40 ng).
The most accurate cut-off was 25 ng, with 79% sensi-
tivity and 89% specificity and an overall accuracy of
84% (95% CI: 0.79–0.89) (Table 2).
Breakdown analysis showed that the sensitivity of
the fecal DNA test was similar for females and males
and was not influenced by age when a cut-off of
69 years, generally adopted as the upper limit in Italian
screening programs, or any other age value was used
(Table 3). Moreover, sensitivity was not significantly
influenced by tumor size or site, and, already high for
tumors in the descending (76%) and ascending (79%)
colon and rectal tract (81%), reached 100% for the
small number of transverse tumors. Finally, there was
a trend towards lower sensitivity for more advanced
stage tumors (chi square for trend, p = 0.057), with the
lowest true positive rate for patients with stage D tu-
mors.
4. Discussion
In recent years, new tests based on the molecular
analysis of fecal DNA have been proposed as promis-
ing tools for the early diagnosis of colorectal cancer.
These tests have the advantage of being non-invasive,
of not requiring bowel preparation, and of being capa-
ble of detecting tumors along the entire length of the
colon and rectum.
Among the molecular targets tested up to now, ge-
nomic DNA integrity extracted from stool has proven
to be potentially useful for discriminating between col-
orectal cancer and normal epithelial cells [5,26,28].
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Table 1
FL-DNA fecal levels as a function of clinical and pathological characteristics
Healthy donors Patients
No. Median (ng) Range No. Median (ng) Range p
All 100 0 0–246 100 64 0–731 <0.0001
Gender
F 57 0 0–246 43 64 0–731
M 43 0 0–207 57 64 0–612 n.s.
Age (years)
69 81 0 0–246 59 68 0–612
>69 19 3 0–38 41 59 0–731 n.s.
Tumor site
Descending 45 58 0–731
Ascending 34 63 0–612
Transverse 5 78 53–157
Rectum 16 72 0–266 n.s.
Dukes’ stage
A 17 77 0–375
B 45 61 0–612
C 29 66 0–731
D 7 28 0–133 n.s.
Tumor size (cm)
0.1–3.9 41 53 0–731
4.0 47 80 0–612 n.s.
Note: n.s. – not significant.
Fig. 1. Receiver operating characteristic (ROC) curve of FL-DNA analysis of the pilot and confirmatory studies.
The results reported by different studies on the diag-
nostic accuracy of fecal DNA are not consistent, prob-
ably due to the different methodologies used [6,20,25]
and to biases occurring during the pre-analytical phase.
Bleeding and inflammation consequent to colonoscopy
can cause falsely elevated long DNA levels and bowel
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Table 2
Sensitivity and specificity of FL-DNA analysis
DNA levels Healthy donors Patients % Sensitivity
(95% CI)
% Specificity
(95% CI)
% Accuracy
(95% CI)
Positive Negative Positive Negative
Cut-offs (ng)
15 22 78 84 16 84 (77–91) 78 (70–86) 81 (76–86)
20 16 84 82 18 82 (76–90) 84 (77–91) 83 (78–88)
25 11 89 79 21 79 (71–87) 89 (83–95) 84 (79–89)
30 8 92 70 30 70 (61–79) 92 (87–97) 81 (76–86)
35 5 95 68 32 68 (59–77) 95 (91–99) 82 (77–87)
40 4 96 65 35 65 (56–74) 96 (92–100) 81 (76–86)
Table 3
Sensitivity and specificity∗ as a function clinical and pathological characteristics
Healthy donors Positive Negative % Specificity Patients Positive Negative % Sensitivity p
(95% CI) (95% CI)
Gender
F 57 8 49 86 (77–95) 43 36 7 84 (73–95)
M 43 3 40 93 (85–100) 57 43 14 75 (64–86) n.s.
Age (years)
69 81 8 73 90 (83–97) 59 47 12 80 (70–90)
>69 19 3 16 84 (68–100) 41 32 9 78 (65–91) n.s.
Tumor site
Descending 45 34 11 76 (64–88)
Ascending 34 27 7 79 (65–93)
Transverse 5 5 0 100
Rectum 16 13 3 81 (62–100) n.s.
Dukes’ stage
A 17 15 2 88 (73–100)
B 45 37 8 82 (71–93)
C 29 21 8 72 (56–88)
D 7 4 3 57 (20–95) n.s.
Tumor size (cm)
0.1–3.9 41 30 11 73 (59–87)
4.0 47 38 9 81 (70–92) n.s.
∗Cut-off value: 25 DNA ng.
n.s. – not significant.
purgation may alter normal colon flora and interfere
with DNA degradation. In our study, the pre-analytical
phase was thus standardized to overcome these poten-
tial biases. In particular, as previously described, fecal
samples from patients in our study were generally ob-
tained several days after colonoscopy to allow for the
restoration the of normal bowel function. Moreover,
stool samples were immediately frozen and stored at
−80◦C for a maximum of 2 months.
In Loktionov’s study [18], it was observed that the
quantity of DNA extracted from stool was higher in
colorectal cancer patients than in healthy individuals,
suggesting that this approach could be useful for the
early diagnosis of colorectal cancer. Recently, other
studies have highlighted the possibility of distinguish-
ing between colorectal cancer patients and healthy in-
dividuals using stool DNA integrity analysis [26,28].
We obtained interesting results of diagnostic relevance
using quantitative long DNA fragment analysis devel-
oped in our laboratory [5].
The use of specific markers such as APC and p53 to
determine DNA integrity rather than random genomic
sequences was a logical follow-on to our previous pa-
pers. Our first study on molecular markers for the diag-
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nosis of colorectal cancer was based on the analysis of
gene alterations [4,21] and on a DNA integrity analysis
comparing a non-quantitative approach, developed by
Ahlquist et al. [1], with our fluorescent methodology
[5], based on the analysis of DNA integrity of these
specific oncogenes as target. In view of the interest-
ing results obtained from these studies, and to maintain
a correct confirmatory study design, we did not change
the methodological approach in the present work.
In the present confirmatory case-control study, we
validated the sensitivity and specificity of this test in a
large and independent case series, and also confirmed
the highest overall diagnostic potential for the 25-ng
cut-off, observed in the pilot study [5]. The diagnostic
potential of the molecular test appears to be indepen-
dent of gender, age and tumor size, in agreement with
the results from other studies [14,15,20]. Moreover, it
was highly effective in detecting transverse colon and
rectal tumors and more successful at detecting early
rather than advanced cancers. This latter finding, which
requires confirmation in a large series of stage D tu-
mors, could be ascribable to a lower cell exfoliation of
primary colorectal cancer in very advanced stages, as
supported by the lower levels of DNA detected in stool
from these patients.
Interestingly, the sensitivity of long DNA evaluation
in detecting colorectal tumors is in line with or slightly
better than that obtained with the most accurate mole-
cular approaches currently available, which are mainly
based on expensive multi-parametric analyses [3,6,14,
15,28]. On the basis of these results and of cost-benefit
considerations, a comparison study is currently being
carried out on the same series of patients to evaluate
the diagnostic potential of circulating DNA, another
simple, rapid and non-invasive approach, which in our
experience has shown to have a high diagnostic accu-
racy [8].
Our next objective will be to verify the diagnostic
potential of the quantitative stool DNA test in symp-
tomatic patients and high-risk individuals and to de-
fine its potential usefulness within large-scale FOBT
screening programs. Moreover, in view of the long nat-
ural history of colorectal cancer evolution [6], a further
interesting application of the test could be for the de-
tection of high risk premalignant lesions. It is known
that a large fraction of high grade adenomas actually
progress into carcinomas. In fact, the sensitivity in de-
tecting these lesions ranges from 20 to 45%, using non-
invasive diagnostic tests based on fecal occult blood
[2,9,17], and only few data are available on molecular
tests [3,6]. The development of a qualitative analysis
of long DNA fragments from stool to identify high-risk
adenomas would therefore constitute an important step
forward in the area of early diagnosis [3,7,27].
In conclusion, too few results are available at present
to propose this molecular test as an alternative to
FOBT in screening programs. For this reason, our next
step will be to validate these findings in a large-scale
cohort study of a screening population, which is nec-
essary prior to implementation into clinical practice.
Ongoing studies are currently exploring the potential
of this molecular approach for unmasking false FOBT
positives to spare patients from invasive colonoscopy.
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